Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
June 22, 2018
- Nippon Zoki Applies for Approval of 3-Day Fentanyl Patch for Cancer Pain
June 22, 2018
- AbbVie, Eisai Launch Pediatric Formulation of Humira
June 22, 2018
- AstraZeneca Completes Transfer of Migraine Drug Zomig to Sawai
June 21, 2018
- Remicade Biosimilar Gets New Dosage Nod for Psoriasis, Crohn’s Disease: Nichi-Iko/Ayumi
June 21, 2018
- Desalex Most Promoted for GPs in April amid Pollen Season: Anterio
June 20, 2018
- PII Data Suggest Acucela’s Emixustat Improves Macular Edema
June 20, 2018
- Enbrel 25 mg Pen Now Available: Pfizer/Takeda
June 19, 2018
- Quizartinib Cuts Risk of Death by 24% for AML: Daiichi Sankyo
June 19, 2018
- Nichi-Iko to Roll Out Enbrel Biosimilar under License Deal with Lupin
June 19, 2018
- Onychomycosis Treatment Efinaconazole Approved in Taiwan: Kaken, Mitsubishi Tanabe
June 18, 2018
- CSL Behring Japan Chief Eyes Double-Digit Growth for Next Few Years
June 18, 2018
- Shionogi Bags Some Asian Rights for Sage’s Depression Drug
June 15, 2018
- Authorized Generics for Aimix, Cravit IV Bag Hit Shelves; Takepron Out in September
June 15, 2018
- Velcade Gx Skips Listing, Teva Takeda Says Not Ready for Launch
June 15, 2018
- Eisai Enters Agreement with 6 Institutions for Nucleic Acid Drug Discovery Research; Project Selected for CiCLE Program
June 14, 2018
- Univ. of Tokyo, Fujitsu, Kowa Discover Novel Small Molecule Compounds Using IT-Based Drug Discovery
June 14, 2018
- US FDA Accepts NDA for Sunovion’s Parkinson’s Disease Treatment
June 14, 2018
- Eisai to Launch New US Research Center for Innovative Drug Discovery in Dementia Field
June 14, 2018
- Mochida Licenses EPA Technologies to Amarin
June 13, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…